Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
March 22, 2021 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica
March 17, 2021 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, March 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical...
Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement
March 02, 2021 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 02, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional and...
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
February 17, 2021 08:00 ET
|
Processa Pharmaceuticals, Inc.
Strengthened Financial Position Supports Execution Through 2023 HANOVER, MD., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a...
Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
January 11, 2021 10:50 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors
November 05, 2020 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
October 13, 2020 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, Md, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Processa Pharmaceuticals Closes $19.2 Million Public Offering
October 06, 2020 16:05 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended...
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
October 02, 2020 06:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA; Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products that...
PROCESSA PHARMACEUTICALS ENTERED INTO A CONTINGENT PRECEDENT IN-LICENSING AGREEMENT WITH ELION ONCOLOGY FOR THE DEVELOPMENT OF ENILURACIL (PCS6422) FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL TUMORS
August 27, 2020 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a contingent precedent exclusive licensing agreement with Elion...